Head-to-head evidence
BEBT-109 vs BPI-7711
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
BEBT-109
Developed by BeBetter Med
NCT06001671 · Phase 1 · completed
This was a small, single-arm, dose-escalation study with no control group and effectively no blinding of participants or investigators; it was designed to find a tolerable dose, not to test whether the drug worked, and results have not yet been reported.
Next expected readout: June 2027 · NCT06514027 (registry estimate)
BPI-7711
Developed by Beta Pharma, Inc.
NCT03812809 · Phase 2 · completed
The trial was an open-label, single-arm study of 226 patients receiving BPI-7711, with no randomized control group for comparison. Its primary endpoint was objective response rate by independent RECIST 1.1 review. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BEBT-109's landscape · BPI-7711's landscape